Abstract
1. A comparative trial of Telepaque and Biloptin is presented, based on 100 consecutive examinations. 2. The comparison is made on visualisation, side-effects and cost. 3. As there are fewer side-effects with Biloptin and no significant difference on the other counts, it is concluded that Biloptin is probably preferable.

This publication has 2 references indexed in Scilit: